Opendata, web and dolomites


Leveraging Small Demethylase inhibitors for Autism Spectrum Disorder

Total Cost €


EC-Contrib. €






 LSDiASD project word cloud

Explore the words cloud of the LSDiASD project. It provides you a very rough idea of what is the project "LSDiASD" about.

inhibition    industrial    syndromes    splitting    remarkable    behaviours    aggregate    erc    disorder    advancing    duplication    dependent    mouse    hemideletion    phenotypes    underlying    wish    clinical    spectrum    point    7q11    broadly    turn    circuits    function    vivo    rescuing    discovered    gtf2i    deficits    core    paradigmatic    region    inroads    despite    symmetrically    traits    rescues    transcription    symptoms    demethylase    alterations    variations    featuring    genetic    diseaseavatars    generalizable    lsd1    neuronal    proof    consistency    grounds    chromosome    treatment    convergence    individuals    prevalent    penetrant    convergent    inhibitors    found    vulnerable    behavioural    few    causative    cnv    hope    plan    models    genes    23    lysine    gene    dosage    chromatin    worldwide    neurodevelopmental    facto    28    caused    associating    modifier    yield    26    diseases    stereotyped    syndrome    prerequisites    business    comprising    efficacy    disability    autism    recapitulating    7dup    inhibitor    therapeutic    competence       language    copy    autistic    de    dissect    impairment    cognitive    points    represses    sociability    consolidator    intellectual    lesions    asd    williams    opposite    400    rare    causing   

Project "LSDiASD" data sheet

The following table provides information about the project.


Organization address
address: Via Festa Del Perdono 7
city: MILANO
postcode: 20122

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 145˙250 €
 EC max contribution 145˙250 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2018-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) coordinator 107˙750.00
2    TTFACTOR SRL IT (MILANO) participant 37˙500.00


 Project objective

Duplication of chromosome region 7q11.23 (7Dup), comprising 26-28 genes, is one of best characterized copy number variations (CNV) causing Autism Spectrum Disorder (ASD), a very prevalent neurodevelopmental condition affecting more than 1% individuals worldwide, and for which no effective treatment is available. Despite the remarkable consistency of core ASD symptoms (impairment in language and sociability along with stereotyped behaviours), over 400 causative genetic lesions have been thus far identified for ASD, splitting it de facto into an aggregate of rare and highly penetrant genetic diseases. In turn, the convergence of symptoms grounds the hope that few paradigmatic syndromes may yield generalizable therapeutic inroads across the autistic spectrum. 7Dup is a case in point since it is symmetrically opposite to Williams Syndrome, a condition caused by 7q11.23 hemideletion and featuring symmetrically opposite phenotypes in language and sociability, thus offering unique opportunities to dissect the dosage-vulnerable circuits that affect language competence and sociability. Specifically, convergent evidence points to transcription factor GTF2I as the key gene underlying the cognitive/behavioural traits of 7Dup. Within my ERC-Consolidator project DISEASEAVATARS we discovered that increased GTF2I dosage represses key genes involved in intellectual disability, autism and neuronal function by associating with lysine demethylase 1 (LSD1), a key chromatin modifier, and found that LSD1 inhibition rescues GTF2I-dependent alterations. Therefore, we now wish to establish in vivo proof of concept for the efficacy of novel LSD1 inhibitors in rescuing cognitive-behavioural deficits in relevant ASD mouse models recapitulating GTF2I CNV, developing an adequate business plan and industrial partnerships as prerequisites for advancing the most effective LSD1 inhibitor towards pre-clinical development for 7Dup and ASD more broadly.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LSDIASD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LSDIASD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NeuroMag (2019)

The Neurological Basis of the Magnetic Sense

Read More  

IMPACCT (2019)

Improved Patient Care by Combinatorial Treatment

Read More  

Life-Inspired (2019)

Life-inspired complex molecular systems controlled by enzymatic reaction networks

Read More